Form 4: Stoke Therapeutics Interim Executive Chair Acquires Stock Options

Arthur Tzianabos, Interim Executive Chair of Stoke Therapeutics, acquires stock options.

Summary

• Arthur Tzianabos, the Interim Executive Chair of Stoke Therapeutics, acquired stock options on March 20, 2025.
• The stock options grant him the right to buy 122,651 shares of common stock at an exercise price of $8.33 per share.
• The options vest ratably over 12 months from the grant date, contingent upon his continued service to Stoke Therapeutics.
• The expiration date for these options is March 19, 2035.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral in sentiment. It reflects standard executive compensation practices.

Positives

• The acquisition of stock options by the Interim Executive Chair aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It's common for executives to receive stock options as part of their compensation packages.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, potentially incentivizing value creation.

Key Dates

Keywords

stock options, Stoke Therapeutics, Arthur Tzianabos, Form 4, executive compensation, beneficial ownership